Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2010
Reporting Period: Events occurring on November 17, 2010, with a scheduled closing for related transactions on November 30, 2010.
Key Financial Metrics and Transaction Details
This filing reports on two distinct asset acquisition and transition agreements rather than standard periodic financial results (e.g., revenue or net income).
| Transaction | Counterparty | Assets Acquired | Total Consideration | Payment Terms |
|---|---|---|---|---|
| Angiotech Agreement | Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH | Lifespan Vascular Graft and related manufacturing business (fixed assets, inventory, permits, legal rights) | $2.8 million | $2.5 million at closing; balance due on first anniversary |
| Edwards Agreements | Edwards Lifesciences, LLC | Distribution business transition (Europe/Japan), inventory, Lifespan trademark | $1.25 million (plus service fees) | $650,000 at closing; $100,000 in 90 days; ~$500,000 for inventory repurchase |
Note: The filing does not provide data on the company's overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Strategic Actions
- Acquisition of Manufacturing: LeMaitre acquired the Lifespan Vascular Graft manufacturing business from Angiotech, excluding cash, accounts receivable, and insurance.
- Market Expansion: LeMaitre entered into agreements to transition the distribution of the Lifespan Vascular Graft in Europe and Japan from Edwards Lifesciences to LeMaitre.
- Inventory Repurchase: LeMaitre agreed to repurchase a portion of Edwards' Lifespan inventory for approximately $500,000.
Outlook, Risks, and Contingencies
- Closing Conditions: The Edwards Agreements are subject to customary closing conditions, with a scheduled closing date of November 30, 2010.
- Non-Competition Covenants: Sellers in the Angiotech Agreement are bound by a three-year non-competition covenant; Edwards is bound by a one-year covenant.
- Transitional Support: Both agreements include provisions for transitional assistance, sales/marketing cooperation, and mutual indemnification for breaches or misrepresentations.
- Service Fees: Future payments to Edwards will include service fees in exchange for continued sales of the product in certain markets.
Investor Verification Checklist
- Verify the successful closing of the Edwards Agreements on or before November 30, 2010.
- Confirm the integration of the Lifespan Vascular Graft manufacturing assets into LeMaitre's operations.
- Monitor the impact of the $2.8 million Angiotech acquisition and $1.25 million Edwards transaction on future cash flow and working capital.
- Review the attached press release (Exhibit 99.1) for additional strategic context not detailed in the 8-K text.